3rd Viral Vector Process Development & Manufacturing Summit
Join Industry Leaders to Shape the Future of Viral Vector Manufacturing!
This year, viral vector-based biotechs have achieved significant milestones, including BLA approvals from Adaptimmune (TECELRA), bluebird bio (LYFGENIA) and Pfizer (BEQVEZ), as well as Genezen’s $18.5M investment in viral vector manufacturing. With 800+ candidates in clinical trials and evolving FDA quality frameworks, the need to improve manufacturability and reduce COGs is urgent.
Returning to Boston, the summit will focus on advancing AAV, AV, and LV processes, from upstream to downstream. Explore cutting-edge technologies, case studies, and innovations in process development to drive scalable, high-quality viral vectors for the future of cell and gene therapeutics.
Join Your Peers to:
Explore practical strategies for maintaining product consistency and safety in large-scale viral vector operations, crucial for regulatory compliance and therapeutic effectiveness, with insights from Sangamo Therapeutics and Kite, A Gilead Company.
Learn from Ultragenyx and Spirovant Sciences about creating standardized manufacturing processes that improve reproducibility and quality control, vital for ensuring therapeutic equivalence across production batches
Explore advanced process optimization techniques for boosting viral yields while maintaining quality, emphasizing the reduction of defective particles that may impact therapeutic results, with insights from St. Jude’s Hospital, Apertura, and UCB
Discuss cutting-edge purification methods from Sanofi that go beyond traditional ultracentrifugation, achieving high-purity viral vectors crucial for effective cell and gene therapies
Who Will You Meet?
Connect with fellow Executive Directors, Vice Presidents, and Principal Scientists specializing in viral vector process development and manufacturing, alongside experts in Analytical Development, Regulatory Affairs, and CMC.
Don’t miss joining this niche community across cell and gene modalities to explore the latest advancements within the viral vector process development and manufacturing realm. These 3-days will feature an in-depth regulatory considerations alignment workshop and technical case studies to transform development cost dynamics.
What Your Peers Have to Say
“I’m looking forward to learning about the latest advances in process development and manufacturing. Anything we as an industry can do to streamline vector production and reduce costs means we have a better chance at getting new therapies to patients who desperately need them.”
April Sena, Vice President, Technical Operations, Life Edit Therapeutics, 2025 Speaker